Ozempic Weight Loss: How GLP-1 Works and Personalization Factors

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) supports weight loss by activating GLP-1 receptors, which regulate appetite, increase satiety, and slow gastric emptying. Clinical data shows average weight loss of 5–15% over 68 weeks in non-diabetic populations, though individual responses vary significantly based on genetics, lifestyle, and metabolic factors.

Weight management with GLP-1 therapy requires more than medication alone—it demands understanding your unique metabolic profile, genetic predispositions, and clinical eligibility. PlexusDx's precision-wellness approach integrates genetic insights with evidence-based compounded options to help you and your provider make informed, personalized treatment decisions.

How GLP-1 Receptor Agonists Work in the Body

GLP-1 (glucagon-like peptide-1) is a natural hormone that regulates blood glucose and appetite. Medications like Ozempic mimic GLP-1 signaling, binding to GLP-1 receptors in the brain, stomach, and intestines. This activation reduces hunger signals, increases fullness sensation, and slows stomach emptying—collectively promoting caloric deficit and weight loss.

The GLP-1 receptor expression varies among individuals due to genetic variation, particularly at the GLP1R locus. Some individuals may have genetic variants associated with stronger or weaker baseline GLP-1 signaling capacity. This genetic context may influence both initial response and optimal dosing, though clinical response is multifactorial and cannot be predicted by genetics alone.

Clinical Evidence and Expected Outcomes with GLP-1 Therapy

Multiple randomized controlled trials document GLP-1 efficacy. The STEP trials (semaglutide) and SUMO trials (tirzepatide) showed sustained weight loss over 68 weeks, with average reductions of 10–21% depending on drug and baseline body weight. Notably, weight loss plateaus typically occur around 12–16 weeks, with maintenance rather than continuous loss thereafter.

Clinical Parameter	Key Finding or Range
Average weight loss (semaglutide)	5–15% body weight over 68 weeks
Time to plateau	12–16 weeks of consistent dosing
Cardiometabolic benefits	Modest BP reduction, improved lipid profiles
Discontinuation weight rebound	30–50% of lost weight regained within 1 year
Genetic influence on response	May contribute 20–40% of individual variation in weight loss

Biomarkers and Genetic Factors That May Influence GLP-1 Response

Your response to GLP-1 therapy depends on multiple pathways: GLP-1 receptor expression (GLP1R rs6923761), satiety regulation (GIPR rs1800437), fat metabolism and appetite (FTO rs9939609), and melanocortin signaling (MC4R rs17782313). These genetic variants exist on a spectrum and may provide context for why some individuals achieve greater weight loss than others.

The PlexusDx Precision Peptide Genetic Test analyzes predispositions across these peptide pathways. Knowing your genetic profile may help inform a more nuanced conversation with your provider about expected response patterns, potential dose adjustments, and complementary lifestyle strategies. Genetic insights should always be interpreted alongside clinical assessment, not as deterministic predictors of outcome.

Branded Ozempic vs. Compounded Semaglutide: Safety and Practical Considerations

Branded Ozempic (manufactured by Novo Nordisk) is FDA-approved for diabetes management and carries established safety data. Compounded semaglutide, prepared by licensed 503A pharmacies, uses the same active pharmaceutical ingredient but differs in manufacturing oversight and formulation specifics. Both require medical supervision; neither is appropriate for self-directed use without provider guidance.

Key differences include regulatory pathway (FDA-approved brand vs. compounded under state pharmacy boards), cost accessibility, and supply reliability. PlexusDx offers compounded semaglutide through licensed 503A facilities starting at $149/mo, providing an alternative route to access GLP-1 therapy when branded options are unavailable or unaffordable. Provider oversight remains essential regardless of source.

Who Should and Should Not Use GLP-1 Therapy: Clinical Eligibility

GLP-1 therapy is appropriate for individuals with BMI ≥27 with weight-related comorbidities or BMI ≥30, alongside sustained lifestyle modifications. Contraindications include personal or family history of medullary thyroid carcinoma, MEN2 syndrome, uncontrolled diabetic retinopathy, and severe kidney disease. Pregnancy, breastfeeding, and pancreatitis history require specialized provider assessment.

A comprehensive pre-treatment evaluation should include metabolic labs (fasting glucose, lipids, liver and kidney function), thyroid screening, and honest discussion of lifestyle capacity. Your provider should assess gastrointestinal history, mental health status (as nausea and appetite suppression may complicate eating disorders), and realistic weight loss expectations. PlexusDx's genetic test can complement this evaluation by providing context on peptide pathway predispositions.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test analyzes four key variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that influence appetite regulation, GLP-1 receptor function, and metabolic rate. This information may help provide context for why individual responses to GLP-1 therapy differ so widely. Your unique genetic profile, combined with clinical labs and lifestyle factors, supports a more complete picture for provider discussion.

The genetic test reveals predispositions in peptide metabolism pathways, not exact medication response or guaranteed weight loss. For example, carrying variants associated with stronger baseline appetite signals may suggest that GLP-1 therapy could address a specific physiologic driver of weight gain in your case. However, genetics account for only part of treatment success; behavior, adherence, sleep, and stress are equally important.

Using genetic insights alongside clinical assessment can support a more informed conversation with your provider about whether GLP-1 therapy aligns with your metabolic profile, what dose range might be appropriate to start, and which complementary interventions (nutritional counseling, exercise, behavioral support) may be most effective for your particular situation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.